Merck Executive Vice President Sells $1.2M in Stock Following FDA Approval and Analyst Revisions
Dean Y. Li, Executive Vice President at Merck & Co (MRK), sold 10,235 shares on February 10, 2026, for about $1.2 million at a weighted average price of $117.5226. After the transaction, Li retains direct ownership of 92,035.05 shares. Separately, Merck secured FDA approval for Keytruda and Keytruda Qlex in a subset of ovarian cancer patients, and …